Etentamig
As of the edition of 20 October 2026, Etentamig is an antibody: in active development; acts on TNFRSF17.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2033
- Kind
- Antibody
- Registered trials
- 16, 0 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF17 | Tumor necrosis factor receptor superfamily member 17 | Q02223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 5 | 0 | 5 | 0 |
| Phase 2 | 6 | 0 | 6 | 0 |
| Phase 3 | 4 | 0 | 4 | 0 |
| All trials | 16 |